Day One Expands Pipeline With Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting Ptk7 in Solid Tumors for Adult and Pediatric Cancers
Day One公司通過針對成人和兒童癌症固體腫瘤的一種潛在的一線臨床期抗體藥物聯合物(ADC)——針對Ptk7的擴大管線。
Day One Expands Pipeline With Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting Ptk7 in Solid Tumors for Adult and Pediatric Cancers
Day One公司通過針對成人和兒童癌症固體腫瘤的一種潛在的一線臨床期抗體藥物聯合物(ADC)——針對Ptk7的擴大管線。
譯文內容由第三人軟體翻譯。